Clinical trials
Chronic Disease trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
69 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 2 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 10 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 49 |
| Unknown status | 9 |
| Recruiting | 4 |
| Terminated | 4 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| McMaster University | 12 |
| Sunnybrook Health Sciences Centre | 4 |
| Western University, Canada | 4 |
| Aurinia Pharmaceuticals Inc. | 3 |
| Hamilton Health Sciences Corporation | 3 |
| Mount Sinai Hospital, Canada | 3 |
| University of Alberta | 3 |
| University of Waterloo | 3 |
| Université du Québec à Chicoutimi | 3 |
| McGill University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chronic Disease | 69 |
| Diabetes Mellitus | 11 |
| Hypertension | 11 |
| Arthritis | 8 |
| Asthma | 5 |
| Cardiovascular Diseases | 5 |
| Diabetes Mellitus, Type 2 | 5 |
| Heart Failure | 5 |
| Obesity | 5 |
| Neoplasms | 4 |
Trials
Showing 1 to 25 of 69. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.